- Home
- PRT vs CVM Comparison
PRT vs CVM Comparison
Compare PRT & CVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PRT | CVM |
|---|---|---|
| Founded | 2017 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.3M | 21.4M |
| IPO Year | N/A | 1996 |
Fundamental Metrics
Financial Performance| Metric | PRT | CVM |
|---|---|---|
| Price | $2.07 | $1.26 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 74.2K | ★ 616.7K |
| Earning Date | 05-13-2026 | 05-13-2026 |
| Dividend Yield | ★ 13.45% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $264,033.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $7.78 | ★ N/A |
| Revenue Growth | N/A | ★ 65.45 |
| 52 Week Low | $1.82 | $0.89 |
| 52 Week High | $4.28 | $13.48 |
Technical Indicators
Market Signals| Indicator | PRT | CVM |
|---|---|---|
| Relative Strength Index (RSI) | 38.04 | 32.09 |
| Support Level | $1.82 | $0.89 |
| Resistance Level | $3.57 | $1.59 |
| Average True Range (ATR) | 0.13 | 0.11 |
| MACD | 0.03 | 0.06 |
| Stochastic Oscillator | 66.67 | 6.72 |
Price Performance
Historical ComparisonAbout PRT PermRock Royalty Trust Trust Units
PermRock Royalty Trust operates as a statutory trust. Its purpose is to own the Net Profits Interest, to distribute to the Trust unitholders cash that it receives in respect of the Net Profits Interest, and to perform certain administrative functions. The Net Profits Interest entitles the trust to receive the net profits from the sale of oil and natural gas production from the underlying properties of its trustor.
About CVM Cel-Sci Corporation
CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.